Sheng Hu

3.7k total citations · 1 hit paper
89 papers, 1.9k citations indexed

About

Sheng Hu is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sheng Hu has authored 89 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 22 papers in Molecular Biology and 19 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sheng Hu's work include Cancer Immunotherapy and Biomarkers (14 papers), Lung Cancer Treatments and Mutations (13 papers) and Virus-based gene therapy research (8 papers). Sheng Hu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (14 papers), Lung Cancer Treatments and Mutations (13 papers) and Virus-based gene therapy research (8 papers). Sheng Hu collaborates with scholars based in China, United States and Taiwan. Sheng Hu's co-authors include Shaozhong Wei, Qian Yu, Hui Xu, Jun Wang, Yuan Wu, Éduardo Bruera, Xiaoxin Yang, Aimée E. Anderson, Xi Lin and Dandan Song and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Scientific Reports.

In The Last Decade

Sheng Hu

80 papers receiving 1.9k citations

Hit Papers

A Comparison of Burnout F... 2020 2026 2022 2024 2020 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A Comparison of Burnout Frequency Among Oncology Physicians and Nurses Working on the Frontline and Usual Wards During the COVID-19 Epidemic in Wuhan, China
    2020 439 citations Sheng Hu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sheng Hu China 22 428 373 366 352 229 89 1.9k
Jingwen Jiang China 29 455 1.1× 1.3k 3.5× 193 0.5× 110 0.3× 87 0.4× 107 2.9k
Yuri Kim South Korea 32 286 0.7× 1.1k 3.0× 89 0.2× 108 0.3× 217 0.9× 223 3.6k
Hamid Saeed Pakistan 26 136 0.3× 313 0.8× 140 0.4× 207 0.6× 69 0.3× 141 2.0k
Eun‐Ok Lee South Korea 30 269 0.6× 1.2k 3.2× 85 0.2× 112 0.3× 290 1.3× 140 2.8k
Seyeon Park South Korea 33 384 0.9× 1.5k 4.0× 79 0.2× 79 0.2× 396 1.7× 153 3.5k
Mohammad Mehedi Hasan Bangladesh 23 119 0.3× 415 1.1× 66 0.2× 93 0.3× 137 0.6× 124 2.0k
Bernard Srour France 32 272 0.6× 395 1.1× 131 0.4× 133 0.4× 111 0.5× 122 5.1k
Chi‐Heum Cho South Korea 33 774 1.8× 891 2.4× 92 0.3× 118 0.3× 73 0.3× 131 3.1k
Liying Dong China 24 116 0.3× 838 2.2× 73 0.2× 53 0.2× 170 0.7× 49 2.6k
Chunling Wang China 17 164 0.4× 362 1.0× 145 0.4× 122 0.3× 26 0.1× 91 1.2k

Countries citing papers authored by Sheng Hu

Since Specialization
Citations

This map shows the geographic impact of Sheng Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sheng Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sheng Hu more than expected).

Fields of papers citing papers by Sheng Hu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sheng Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sheng Hu. The network helps show where Sheng Hu may publish in the future.

Co-authorship network of co-authors of Sheng Hu

This figure shows the co-authorship network connecting the top 25 collaborators of Sheng Hu. A scholar is included among the top collaborators of Sheng Hu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sheng Hu. Sheng Hu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Xiao, Hua, Zhaoying Yao, Tao Li, et al.. (2025). SERPINH1 secretion by cancer-associated fibroblasts promotes hepatocellular carcinoma malignancy through SENP3-mediated SP1/SQLE pathway. International Immunopharmacology. 150. 114259–114259. 1 indexed citations
2.
3.
Wang, Jun, Xiaojing Li, Shuang Dong, et al.. (2025). Case report: Personalized management of treatment resistance in advanced NSCLC patients with mutated epidermal growth factor receptor: special examples and literature review. Frontiers in Oncology. 15. 1525881–1525881. 1 indexed citations
4.
Wu, Xinxin, Caiyun Zhang, Sheng Hu, et al.. (2025). The Role of Lactate and Lactylation in the Dysregulation of Immune Responses in Psoriasis. Clinical Reviews in Allergy & Immunology. 68(1). 28–28. 3 indexed citations
5.
Li, Ziming, Zhengbo Song, Nong Yang, et al.. (2024). SHR-A1811 (antibody-drug conjugate) in advanced HER2-mutant non-small cell lung cancer: a multicenter, open-label, phase 1/2 study. Signal Transduction and Targeted Therapy. 9(1). 182–182. 13 indexed citations
6.
Xiao, Tianlin, Sheng Hu, Shuang Dong, et al.. (2024). A study on combination of non-ablative local RFA with PD-1 and angiogenesis blocking to prolong survival through improvement of immune microenvironment in advanced Hepatocellular Carcinoma. International Immunopharmacology. 134. 112144–112144. 1 indexed citations
7.
Zhang, Chunxue, Yuxiang Fei, Hui Wang, et al.. (2023). CAFs orchestrates tumor immune microenvironment—A new target in cancer therapy?. Frontiers in Pharmacology. 14. 67 indexed citations
8.
Hu, Sheng, Bing Leng, Jinjiao Jiang, et al.. (2023). An HPLC-MS/MS method for determination of sulbactam in human plasma and its pharmacokinetic application in critically ill patients with augmented renal clearance. International Journal of Clinical Pharmacology and Therapeutics. 61(8). 329–338. 1 indexed citations
9.
Yang, Kai, Sheng Hu, Jun Huang, et al.. (2023). Modification of the 4-Hydroxyphenylacetate-3-hydroxylase Substrate Pocket to Increase Activity towards Resveratrol. Molecules. 28(14). 5602–5602. 9 indexed citations
10.
Li, Bo, Junqiu Yue, Jian Chen, et al.. (2023). Dynamic RBM47 ISGylation confers broad immunoprotection against lung injury and tumorigenesis via TSC22D3 downregulation. Cell Death Discovery. 9(1). 430–430. 3 indexed citations
11.
Shi, Le, Yang Shu, Xiangdong Hu, et al.. (2022). An Optimized Two-Herb Chinese Food as Medicine Formula Reduces Cisplatin-Induced Nephrotoxicity in the Treatment of Lung Cancer in Mice. Frontiers in Pharmacology. 13. 827901–827901. 10 indexed citations
12.
13.
Wang, Tao, Shibo Zhang, Yaqiong Liu, et al.. (2022). Local application of triamcinolone acetonide-conjugated chitosan membrane to prevent benign biliary stricture. Drug Delivery and Translational Research. 12(12). 2895–2906. 1 indexed citations
14.
Hu, Sheng, Xuejun Wang, Tao Wang, et al.. (2022). Differential enrichment of H3K9me3 in intrahepatic cholangiocarcinoma. BMC Medical Genomics. 15(1). 185–185. 3 indexed citations
15.
Wang, Jianan, Bo Zhou, Xiangdong Hu, et al.. (2021). Deciphering the Formulation Secret Underlying Chinese Huo-Clearing Herbal Drink. Frontiers in Pharmacology. 12. 654699–654699. 8 indexed citations
16.
17.
Lu, Yuan, Yu He, Xiaoke Liu, et al.. (2021). Strategies to package recombinant Adeno-Associated Virus expressing the N-terminal gasdermin domain for tumor treatment. Nature Communications. 12(1). 7155–7155. 40 indexed citations
18.
Ducreux, Michel, Ghassan K. Abou‐Alfa, Zhenggang Ren, et al.. (2021). O-1 Results from a global phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with unresectable hepatocellular carcinoma. Annals of Oncology. 32. S217–S217. 25 indexed citations
19.
Xie, Rong, Jing Tang, Sheng Hu, & Hui Jiang. (2017). Diffuse large B cell lymphoma-related prognostic factors, Ki-67 and Bcl-6 expression levels. Biomedical Research-tokyo. 28(15). 6740–6742.
20.
Hu, Sheng. (1994). Clinical and demographic characteristics of adult emergency patients at the Taipei Veterans General Hospital.. PubMed. 93(1). 61–5. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jingwen Jiang Breakdown of academic impact, for papers by Yuri Kim Breakdown of academic impact, for papers by Hamid Saeed Breakdown of academic impact, for papers by Eun‐Ok Lee Breakdown of academic impact, for papers by Seyeon Park Breakdown of academic impact, for papers by Mohammad Mehedi Hasan Breakdown of academic impact, for papers by Bernard Srour Breakdown of academic impact, for papers by Chi‐Heum Cho Breakdown of academic impact, for papers by Liying Dong Breakdown of academic impact, for papers by Chunling Wang
Rankless by CCL
2026